Biogen | BIIB - Zinsaufwendungen Für Schuld

Aktienkurs
184.38
Täglich Wechseln
-3.50 -1.86%
Monatlich
-2.54%
Jährlich
55.15%
Q2 Prognose
180.43




Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 740M 40M 2025-06
Acadia Pharmaceuticals USD 0 4.12M 2024-09
ALKERMES USD 12.28M 7.63M 2025-12
Amgen USD 653M 32M 2025-12
Bayer EUR 675M 87M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Gilead Sciences USD 255M 1000K 2025-12
Incyte USD 582K 10K 2025-12
Merck USD 412M 85M 2025-12
Moderna USD 12.14B 12.13B 2025-09
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 304M 23M 2025-12
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 178M 203M 2026-03
Sanofi EUR -25M 99.78M 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Teva Pharmaceutical Industries USD 220M 17M 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
United Therapeutics USD 3.1M 100K 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12